胰腺神经内分泌瘤的精准诊疗进展

高鹤丽; 徐近; 陈洁; 虞先濬

doi:10.19401/j.cnki.1007-3639.2023.11.004

您当前的位置：

首页 >

文章列表页 >

胰腺神经内分泌瘤的精准诊疗进展

专家述评 | 更新时间：2025-12-31

- 胰腺神经内分泌瘤的精准诊疗进展
- Updates on precision medicine of pancreatic neuroendocrine tumor
- 中国癌症杂志 2023年33卷第11期页码：993-1001
- 作者机构：
  
  1. 复旦大学附属肿瘤医院胰腺外科，复旦大学上海医学院肿瘤学系，复旦大学胰腺肿瘤研究所，上海市胰腺肿瘤研究所，上海 200032
  2. 复旦大学附属肿瘤医院神经内分泌肿瘤中心，头颈及神经内分泌肿瘤内科，复旦大学上海医学院肿瘤学系，上海 200032
- 作者简介：
  
  [ "高鹤丽（ORCID: 0000-0001-6094-5776），博士，主治医师。" ]
  [ "陈洁，主任医师，教授，博士研究生导师。现任复旦大学附属肿瘤医院神经内分泌肿瘤多学科首席专家，复旦大学附属肿瘤医院神经内分泌肿瘤中心主任，复旦大学附属肿瘤医院头颈及神经内分泌肿瘤内科主任。担任欧洲神经内分泌肿瘤学会顾问委员会委员，欧洲肿瘤内科学会神经内分泌及内分泌肿瘤学组委员，国际神经内分泌肿瘤联盟医疗顾问委员会委员，中国抗癌协会神经内分泌肿瘤专业委员会主任委员，中国抗癌协会胰腺癌专业委员会神经内分泌肿瘤学组组长，中国抗癌协会肿瘤内分泌专业委员会副主任委员，中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组副组长，中国医师协会胰腺病专业委员会胰腺神经内分泌肿瘤专业委员会副主任委员，中国临床肿瘤学会罕见肿瘤专家委员会委员，中国抗癌协会理事，上海市抗癌协会常务理事。欧洲神经内分泌肿瘤学会官方杂志Journal of Neuroendocrinology高级编委，Journal of Pancreatology编委，《中国癌症杂志》编委。" ]
  [ "虞先濬，主任医师，二级教授，博士研究生导师。现任复旦大学附属肿瘤医院院长，上海市胰腺肿瘤研究所所长，复旦大学胰腺肿瘤研究所所长。国家杰出青年科学基金获得者，国家科技部“中青年科技创新领军人才”，国家百千万人才工程“有突出贡献中青年专家”，全国五一劳动奖章获得者，上海市领军人才，上海工匠，上海市科技精英。享受国务院政府特殊津贴。担任中国抗癌协会胰腺癌专业委员会主任委员，中国胰腺癌多学科协作组组长，中华医学会外科学分会胰腺外科学组委员，中国医师协会胰腺病专业委员会委员，中国临床肿瘤学会胰腺癌专家委员会常务委员等职务。" ]
- 基金信息：
  
  国家自然科学基金“罕见肿瘤研究专项”项目(82141104)
- DOI：10.19401/j.cnki.1007-3639.2023.11.004
  中图分类号： R735.9
- 收稿：2023-07-18，
  
  修回：2023-10-30，
  
  纸质出版：2023-11-30
- 稿件说明：
移动端阅览
高鹤丽, 徐近, 陈洁, 等. 胰腺神经内分泌瘤的精准诊疗进展[J]. 中国癌症杂志, 2023,33(11):993-1001.

Heli GAO, Jin XU, Jie CHEN, et al. Updates on precision medicine of pancreatic neuroendocrine tumor[J]. China Oncology, 2023, 33(11): 993-1001.
高鹤丽, 徐近, 陈洁, 等. 胰腺神经内分泌瘤的精准诊疗进展[J]. 中国癌症杂志, 2023,33(11):993-1001. DOI： 10.19401/j.cnki.1007-3639.2023.11.004.

Heli GAO, Jin XU, Jie CHEN, et al. Updates on precision medicine of pancreatic neuroendocrine tumor[J]. China Oncology, 2023, 33(11): 993-1001. DOI： 10.19401/j.cnki.1007-3639.2023.11.004.

摘要

自2011年肿瘤精准医疗的概念提出后，实体肿瘤的治疗逐渐迈入以基因检测和靶向治疗为主导的精准医学时代。作为少见肿瘤，胰腺神经内分泌瘤（pancreatic neuroendocrine tumor，PanNET）的发病率逐年升高，既往以分期、分级、分化为基础的临床病理学因素作为PanNET治疗选择和预后预测的指标，没有精准标志物用于判断PanNET预后及指导其治疗药物的选择。随着临床医师对PanNET的诊断、治疗和预后预测等方面的认识更新，以及基因组学和分子检测在PanNET中的深入研究，精准医疗能否给PanNET的诊治和预后预测带来新的变革?本文通过回顾最新文献阐述PanNET精准诊疗现状。

Abstract

Since the concept of precision medicine proposed in 2011

the treatment of solid tumors has entered era of precision medicine led by gene testing. As a rare tumor

the incidence rate of pancreatic neuroendocrine tumor (PanNET) is increasing gradually. In the past

clinicopathological factors such as stage and grade system were used as criteria in the diagnosis and prognostic prediction of PanNET patients

and there were few biomarkers guiding the selection of PanNET diagnosis and treatment. As the diagnosis

treatment and prognosis of PanNET have been updated these years

and genomics and molecular testing are wildly used in PanNET research

can precision bring new changes to the diagnosis

treatment and prognostic prediction of PanNET? This article reviewed the current status of PanNET precision therapy through the latest literature.

关键词

Keywords

references

BECKMANN J S , LEW D . Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities [J ] . Genome Med , 2016 , 8 ( 1 ): 134 .

PARK J J H , HSU G , SIDEN E G , et al . An overview of precision oncology basket and umbrella trials for clinicians [J ] . CA A Cancer J Clin , 2020 , 70 ( 2 ): 125 - 137 . DOI: 10.3322/caac.v70.2 http://doi.org/10.3322/caac.v70.2 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/70/2 https://acsjournals.onlinelibrary.wiley.com/toc/15424863/70/2

SATPATHY S , JAEHNIG E J , KRUG K , et al . Microscaled proteogenomic methods for precision oncology [J ] . Nat Commun , 2020 , 11 ( 1 ): 532 . DOI: 10.1038/s41467-020-14381-2 http://doi.org/10.1038/s41467-020-14381-2

LLOYD R V , OSAMURA R Y , KLOPPEL G , et al . WHO classification of tumours of endocrine organs [M ] . 4th ed, Lyon : International Agency for Research on Cancer (IARC) Press , 2017 : 11 - 64 .

SZYBOWSKA M , METE O , WEBER E , et al . Neuroendocrine neoplasms associated with germline pathogenic variants in the homologous recombination pathway [J ] . Endocr Pathol , 2019 , 30 ( 3 ): 237 - 245 . DOI: 10.1007/s12022-019-9569-4 http://doi.org/10.1007/s12022-019-9569-4

ALREZK R , HANNAH-SHMOUNI F , STRATAKIS C A . MEN4 and CDKN1B mutations: the latest of the MEN syndromes [J ] . Endocr Relat Cancer , 2017 , 24 ( 10 ): T195 -T208. DOI: 10.1530/ERC-17-0243 http://doi.org/10.1530/ERC-17-0243 https://erc.bioscientifica.com/view/journals/erc/24/10/ERC-17-0243.xml https://erc.bioscientifica.com/view/journals/erc/24/10/ERC-17-0243.xml

UCCELLA S , LA ROSA S , METOVIC J , et al . Genomics of high-grade neuroendocrine neoplasms: well-differentiated neuroendocrine tumor with high-grade features (G3 NET) and neuroendocrine carcinomas (NEC) of various anatomic sites [J ] . Endocr Pathol , 2021 , 32 ( 1 ): 192 - 210 . DOI: 10.1007/s12022-020-09660-z http://doi.org/10.1007/s12022-020-09660-z

BOCCHINI M , NICOLINI F , SEVERI S , et al . Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management-an updated review [J ] . Front Oncol , 2020 , 10 : 831 . DOI: 10.3389/fonc.2020.00831 http://doi.org/10.3389/fonc.2020.00831

ÖBERG K , CALIFANO A , STROSBERG J R , et al . A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood [J ] . Ann Oncol , 2020 , 31 ( 2 ): 202 - 212 . DOI: S0923-7534(19)39084-2 http://doi.org/S0923-7534(19)39084-2

MAPELLI P , BEZZI C , MUFFATTI F , et al . Somatostatin receptor activity assessed by 68 Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors [J ] . Eur J Nucl Med Mol Imaging , 2023 , 50 ( 9 ): 2818 - 2829 . DOI: 10.1007/s00259-023-06210-7 http://doi.org/10.1007/s00259-023-06210-7

ROZENBLUM L , MOKRANE F Z , YEH R , et al . Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: a step-by-step approach [J ] . Eur J Radiol , 2020 , 122 : 108743 . DOI: 10.1016/j.ejrad.2019.108743 http://doi.org/10.1016/j.ejrad.2019.108743 https://linkinghub.elsevier.com/retrieve/pii/S0720048X19303936 https://linkinghub.elsevier.com/retrieve/pii/S0720048X19303936

BINDERUP T , KNIGGE U , JOHNBECK C B , et al . 18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study [J ] . J Nucl Med , 2021 , 62 ( 6 ): 808 - 815 . DOI: 10.2967/jnumed.120.244798 http://doi.org/10.2967/jnumed.120.244798 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.244798 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.120.244798

PRIESTLEY P , BABER J , LOLKEMA M P , et al . Pan-cancer whole-genome analyses of metastatic solid tumours [J ] . Nature , 2019 , 575 ( 7781 ): 210 - 216 . DOI: 10.1038/s41586-019-1689-y http://doi.org/10.1038/s41586-019-1689-y

CAO Y N , ZHOU W W , LI L , et al . Pan-cancer analysis of somatic mutations across 21 neuroendocrine tumor types [J ] . Cell Res , 2018 , 28 ( 5 ): 601 - 604 . DOI: 10.1038/s41422-018-0019-5 http://doi.org/10.1038/s41422-018-0019-5

SCARPA A , CHANG D K , NONES K , et al . Whole-genome landscape of pancreatic neuroendocrine tumours [J ] . Nature , 2017 , 543 ( 7643 ): 65 - 71 . DOI: 10.1038/nature21063 http://doi.org/10.1038/nature21063 https://www.nature.com/articles/nature21063 https://www.nature.com/articles/nature21063

JIAO Y C , SHI C J , EDIL B H , et al . DAXX/ATRX,MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors [J ] . Science , 2011 , 331 ( 6021 ): 1199 - 1203 . DOI: 10.1126/science.1200609 http://doi.org/10.1126/science.1200609 https://www.science.org/doi/10.1126/science.1200609 https://www.science.org/doi/10.1126/science.1200609

YAMAUCHI Y , KODAMA Y , SHIOKAWA M , et al . Rb and p53 execute distinct roles in the development of pancreatic neuroendocrine tumors [J ] . Cancer Res , 2020 , 80 ( 17 ): 3620 - 3630 . DOI: 10.1158/0008-5472.CAN-19-2232 http://doi.org/10.1158/0008-5472.CAN-19-2232

WHO Classification of Tumours Editorial Board . Endocrine and Neuroendocrine tumours [S/OL ] . 5th ed. Lyon (France) : International Agency for Research on Cancer , 2022 [2023-08-11 ] . https://tumourclassification.larc.who.int/charpters/53. https://tumourclassification.larc.who.int/charpters/53 https://tumourclassification.larc.who.int/charpters/53

GAO H L , LIU L , WANG W Q , et al . Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor [J ] . Cancer Lett , 2018 , 412 : 188 - 193 . DOI: S0304-3835(17)30673-0 http://doi.org/S0304-3835(17)30673-0

WANG W Q , ZHANG W H , GAO H L , et al . A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors [J ] . J Gastroenterol , 2021 , 56 ( 4 ): 395 - 405 . DOI: 10.1007/s00535-021-01777-0 http://doi.org/10.1007/s00535-021-01777-0

TITAN A L , NORTON J A , FISHER A T , et al . Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors [J ] . JAMA Netw Open , 2020 , 3 ( 11 ): e202 4318.

HACKENG W M , BROSENS L A A , KIM J Y , et al . Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size [J ] . Gut , 2022 , 71 ( 5 ): 961 - 973 . DOI: 10.1136/gutjnl-2020-322595 http://doi.org/10.1136/gutjnl-2020-322595 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-322595 https://gut.bmj.com/lookup/doi/10.1136/gutjnl-2020-322595

ALTIMARI M , ABAD J , CHAWLA A . The role of oncologic resection and enucleation for small pancreatic neuroendocrine tumors [J ] . HPB , 2021 , 23 ( 10 ): 1533 - 1540 . DOI: 10.1016/j.hpb.2021.03.005 http://doi.org/10.1016/j.hpb.2021.03.005

CEJAS P , DRIER Y , DREIJERINK K M A , et al . Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors [J ] . Nat Med , 2019 , 25 ( 8 ): 1260 - 1265 . DOI: 10.1038/s41591-019-0493-4 http://doi.org/10.1038/s41591-019-0493-4

HACKENG W M , SCHELHAAS W , MORSINK F H M , et al . Alternative lengthening of telomeres and differential expression of endocrine transcription factors distinguish metastatic and non-metastatic insulinomas [J ] . Endocr Pathol , 2020 , 31 ( 2 ): 108 - 118 . DOI: 10.1007/s12022-020-09611-8 http://doi.org/10.1007/s12022-020-09611-8

HUA J , SHI S , XU J , et al . Expression patterns and prognostic value of DNA damage repair proteins in resected pancreatic neuroendocrine neoplasms [J ] . Ann Surg , 2022 , 275 ( 2 ): e443 -e452. DOI: 10.1097/SLA.0000000000003884 http://doi.org/10.1097/SLA.0000000000003884 https://journals.lww.com/10.1097/SLA.0000000000003884 https://journals.lww.com/10.1097/SLA.0000000000003884

RIZZO F M , MEYER T . Liquid biopsies for neuroendocrine tumors: circulating tumor cells, DNA, and microRNAs [J ] . Endocrinol Metab Clin N Am , 2018 , 47 ( 3 ): 471 - 483 . DOI: 10.1016/j.ecl.2018.04.002 http://doi.org/10.1016/j.ecl.2018.04.002 https://linkinghub.elsevier.com/retrieve/pii/S0889852918305140 https://linkinghub.elsevier.com/retrieve/pii/S0889852918305140

KHAN M S , KIRKWOOD A A , TSIGANI T , et al . Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms [J ] . Clin Cancer Res , 2016 , 22 ( 1 ): 79 - 85 . DOI: 10.1158/1078-0432.CCR-15-1008 http://doi.org/10.1158/1078-0432.CCR-15-1008

MANDAIR D , KHAN M S , LOPES A , et al . Prognostic threshold for circulating tumor cells in patients with pancreatic and midgut neuroendocrine tumors [J ] . J Clin Endocrinol Metab , 2021 , 106 ( 3 ): 872 - 882 . DOI: 10.1210/clinem/dgaa822 http://doi.org/10.1210/clinem/dgaa822

ZAKKA K , NAGY R , DRUSBOSKY L , et al . Blood-based next-generation sequencing analysis of neuroendocrine neoplasms [J ] . Oncotarget , 2020 , 11 ( 19 ): 1749 - 1757 . DOI: 10.18632/oncotarget.27588 http://doi.org/10.18632/oncotarget.27588

FINNERTY B M , GRAY K D , MOORE M D , et al . Epigenetics of gastroenteropancreatic neuroendocrine tumors: a clinicopathologic perspective [J ] . World J Gastrointest Oncol , 2017 , 9 ( 9 ): 341 - 353 . DOI: 10.4251/wjgo.v9.i9.341 http://doi.org/10.4251/wjgo.v9.i9.341 http://www.wjgnet.com/1948-5204/full/v9/i9/341.htm http://www.wjgnet.com/1948-5204/full/v9/i9/341.htm

PANARELLI N , TYRYSHKIN K , WONG J J M , et al . Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing [J ] . Endocr Relat Cancer , 2019 , 26 ( 1 ): 47 - 57 . DOI: 10.1530/ERC-18-0244 http://doi.org/10.1530/ERC-18-0244 https://erc.bioscientifica.com/view/journals/erc/26/1/ERC-18-0244.xml https://erc.bioscientifica.com/view/journals/erc/26/1/ERC-18-0244.xml

KLIESER E , URBAS R , SWIERCZYNSKI S , et al . HDAC-linked proliferative miRNA expression pattern in pancreatic neuroendocrine tumors [J ] . Int J Mol Sci , 2018 , 19 ( 9 ): 2781 . DOI: 10.3390/ijms19092781 http://doi.org/10.3390/ijms19092781 http://www.mdpi.com/1422-0067/19/9/2781 http://www.mdpi.com/1422-0067/19/9/2781

MALCZEWSKA A , WITKOWSKA M , WÓJCIK-GIERTUGA M , et al . Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS center of excellence experience [J ] . Neuroendocrinology , 2021 , 111 ( 4 ): 304 - 319 . DOI: 10.1159/000508106 http://doi.org/10.1159/000508106 https://www.karger.com/Article/FullText/508106 https://www.karger.com/Article/FullText/508106

CHIRINDE A . Impact on clinical management of a novel blood-derived liquid biopsy (NETest) in patients with neuroendocrine tumors [C ] . ENETS conferenc , 2023 .

BODEI L S , KIDD M S , SINGH A , et al . PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest [J ] . Eur J Nucl Med Mol Imaging , 2020 , 47 ( 4 ): 895 - 906 . DOI: 10.1007/s00259-019-04601-3 http://doi.org/10.1007/s00259-019-04601-3

MALCZEWSKA A , KOS-KUDŁA B , KIDD M , et al . The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors [J ] . Adv Med Sci , 2020 , 65 ( 1 ): 18 - 29 . DOI: 10.1016/j.advms.2019.10.002 http://doi.org/10.1016/j.advms.2019.10.002 https://linkinghub.elsevier.com/retrieve/pii/S1896112619300124 https://linkinghub.elsevier.com/retrieve/pii/S1896112619300124

LE TOURNEAU C , DELORD J P , GONÇALVES A , et al . Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial [J ] . Lancet Oncol , 2015 , 16 ( 13 ): 1324 - 1334 . DOI: 10.1016/S1470-2045(15)00188-6 http://doi.org/10.1016/S1470-2045(15)00188-6

HORAK P , HEINING C , KREUTZFELDT S , et al . Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers [J ] . Cancer Discov , 2021 , 11 ( 11 ): 2780 - 2795 . DOI: 10.1158/2159-8290.CD-21-0126 http://doi.org/10.1158/2159-8290.CD-21-0126

BOILÈVE A , FARON M , FODIL-CHERIF S , et al . Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data [J ] . Eur J Cancer , 2023 , 186 : 122 - 132 . DOI: 10.1016/j.ejca.2023.03.024 http://doi.org/10.1016/j.ejca.2023.03.024

GAUDENZI G , DICITORE A , CARRA S , et al . MANAGEMENT OF ENDOCRINE DISEASE: precision medicine in neuroendocrine neoplasms: an update on current management and future perspectives [J ] . Eur J Endocrinol , 2019 , 181 ( 1 ): R1 -R10. DOI: 10.1530/EJE-19-0021 http://doi.org/10.1530/EJE-19-0021 https://academic.oup.com/ejendo/article/181/1/R1/6654183 https://academic.oup.com/ejendo/article/181/1/R1/6654183

CAPLIN M E , PAVEL M , ĆWIKŁA J B , et al . Lanreotide in metastatic enteropancreatic neuroendocrine tumors [J ] . N Engl J Med , 2014 , 371 ( 3 ): 224 - 233 . DOI: 10.1056/NEJMoa1316158 http://doi.org/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158 http://www.nejm.org/doi/10.1056/NEJMoa1316158

RINKE A , MÜLLER H H , SCHADE-BRITTINGER C , et al . Placebo-controlled,double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group [J ] . J Clin Oncol , 2009 , 27 ( 28 ): 4656 - 4663 . DOI: 10.1200/JCO.2009.22.8510 http://doi.org/10.1200/JCO.2009.22.8510 https://ascopubs.org/doi/10.1200/JCO.2009.22.8510 https://ascopubs.org/doi/10.1200/JCO.2009.22.8510

CHEN L H , JUMAI N , HE Q , et al . The role of quantitative tumor burden based on[ 68 Ga ] Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis [J ] . Eur J Nucl Med Mol Imaging , 2023 , 50 ( 2 ): 525 - 534 . DOI: 10.1007/s00259-022-05971-x http://doi.org/10.1007/s00259-022-05971-x

CHI Y , SONG L , LIU W , et al . S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): a randomised, open-label, multicentre phase 2 trial [J ] . eClinicalMedicine , 2022 , 54 : 101667 . DOI: 10.1016/j.eclinm.2022.101667 http://doi.org/10.1016/j.eclinm.2022.101667 https://linkinghub.elsevier.com/retrieve/pii/S2589537022003972 https://linkinghub.elsevier.com/retrieve/pii/S2589537022003972

KUNZ P L , CATALANO P J , NIMEIRI H S , et al . A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211) [J ] . J Clin Oncol , 2015 , 33 ( 15 _suppl): TPS4145 . DOI: 10.1200/jco.2015.33.15_suppl.tps4145 http://doi.org/10.1200/jco.2015.33.15_suppl.tps4145 http://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.tps4145 http://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.tps4145

WANG W , ZHANG Y , PENG Y , et al . A ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study [J ] . Neuroendocrinology , 2021 , 111 ( 8 ): 752 - 763 . DOI: 10.1159/000510159 http://doi.org/10.1159/000510159 https://www.karger.com/Article/FullText/510159 https://www.karger.com/Article/FullText/510159

CHILDS A , KIRKWOOD A , EDELINE J , et al . Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours [J ] . Endocr Relat Cancer , 2016 , 23 ( 7 ): 563 - 570 . DOI: 10.1530/ERC-16-0099 http://doi.org/10.1530/ERC-16-0099 https://erc.bioscientifica.com/view/journals/erc/23/7/563.xml https://erc.bioscientifica.com/view/journals/erc/23/7/563.xml

PELLAT A , DREYER C , COUFFIGNAL C , et al . Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms [J ] . Neuroendocrinology , 2018 , 107 ( 1 ): 24 - 31 . DOI: 10.1159/000487237 http://doi.org/10.1159/000487237

ZURITA A J , KHAJAVI M , WU H K , et al . Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours [J ] . Br J Cancer , 2015 , 112 ( 7 ): 1199 - 1205 . DOI: 10.1038/bjc.2015.73 http://doi.org/10.1038/bjc.2015.73

LIVERANI C , SPADAZZI C , IBRAHIM T , et al . HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors [J ] . Front Endocrinol (Lausanne) , 2022 , 13 : 1045038 . DOI: 10.3389/fendo.2022.1045038 http://doi.org/10.3389/fendo.2022.1045038 https://www.frontiersin.org/articles/10.3389/fendo.2022.1045038/full https://www.frontiersin.org/articles/10.3389/fendo.2022.1045038/full

CHEN L , WANG W , JIN K , et al . Special issue “The advance of solid tumor research in China”: prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors [J ] . Int J Cancer , 2023 , 152 ( 1 ): 90 - 99 . DOI: 10.1002/ijc.v152.1 http://doi.org/10.1002/ijc.v152.1 https://onlinelibrary.wiley.com/toc/10970215/152/1 https://onlinelibrary.wiley.com/toc/10970215/152/1

CHEN H , LI Z , HU Y , et al . Maximum value on arterial phase computed tomography predicts prognosis and treatment efficacy of sunitinib for pancreatic neuroendocrine tumours [J ] . Ann Surg Oncol , 2023 , 30 ( 5 ): 2988 - 2998 . DOI: 10.1245/s10434-022-12693-9 http://doi.org/10.1245/s10434-022-12693-9

YAO J C , PHAN A T , HESS K , et al . Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors [J ] . Pancreas , 2015 , 44 ( 2 ): 190 - 197 . DOI: 10.1097/MPA.0000000000000255 http://doi.org/10.1097/MPA.0000000000000255 https://journals.lww.com/00006676-201503000-00003 https://journals.lww.com/00006676-201503000-00003

YAO J , GARG A , CHEN D , et al . Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials [J ] . Endocr Relat Cancer , 2019 , 26 ( 4 ): 391 - 403 . DOI: 10.1530/ERC-18-0332 http://doi.org/10.1530/ERC-18-0332 https://erc.bioscientifica.com/view/journals/erc/26/4/ERC-18-0332.xml https://erc.bioscientifica.com/view/journals/erc/26/4/ERC-18-0332.xml

DI NICOLANTONIO F , ARENA S , TABERNERO J , et al . Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus [J ] . J Clin Invest , 2010 , 120 ( 8 ): 2858 - 2866 . DOI: 10.1172/JCI37539 http://doi.org/10.1172/JCI37539

CHANG T M , SHAN Y S , CHU P Y , et al . The regulatory role of aberrant phosphatase and tensin homologue and liver kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors [J ] . Oncotarget , 2017 , 8 ( 58 ): 98068 - 98083 . DOI: 10.18632/oncotarget.v8i58 http://doi.org/10.18632/oncotarget.v8i58 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.v8i58 https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.v8i58

SERRA S , ZHENG L , HASSAN M , et al . The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy [J ] . Cancer Res , 2012 , 72 ( 22 ): 5683 - 5691 . DOI: 10.1158/0008-5472.CAN-12-2102 http://doi.org/10.1158/0008-5472.CAN-12-2102

MPILLA G B , UDDIN M H , AL-HALLAK M N , et al . PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus [J ] . Mol Cancer Ther , 2021 , 20 ( 10 ): 1836 - 1845 . DOI: 10.1158/1535-7163.MCT-20-1105 http://doi.org/10.1158/1535-7163.MCT-20-1105

ZAKNUN J J , BODEI L , MUELLER-BRAND J , et al . The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours [J ] . Eur J Nucl Med Mol Imaging , 2013 , 40 ( 5 ): 800 - 816 . DOI: 10.1007/s00259-012-2330-6 http://doi.org/10.1007/s00259-012-2330-6 http://link.springer.com/10.1007/s00259-012-2330-6 http://link.springer.com/10.1007/s00259-012-2330-6

BODEI L , RAJ N , DO R K , et al . Interim analysis of a prospective validation of 2 blood-based genomic assessments (PPQ and NETest) to determine the clinical efficacy of 177Lu-DOTATATE in neuroendocrine tumors [J ] . J Nucl Med , 2023 , 64 ( 4 ): 567 - 573 . DOI: 10.2967/jnumed.122.264363 http://doi.org/10.2967/jnumed.122.264363 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.122.264363 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.122.264363

DESMAISON C , NICCOLI P , OZIEL TAIEB S , et al . Transarterial chemoembolization (TACE) for neuroendocrine liver metastasis (NELM): predictive value of volumetric arterial enhancement (VAE) on baseline MRI [J ] . Bull Cancer , 2023 , 110 ( 3 ): 308 - 319 . DOI: 10.1016/j.bulcan.2022.12.007 http://doi.org/10.1016/j.bulcan.2022.12.007

SAHU S , SCHERNTHANER R , ARDON R , et al . Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: can enhancing tumor burden of the whole liver help predict patient survival? [J ] . Radiology , 2017 , 283 ( 3 ): 883 - 894 . DOI: 10.1148/radiol.2016160838 http://doi.org/10.1148/radiol.2016160838

LIU Y M , CHEN W C , CUI W , et al . Quantitative pretreatment CT parameters as predictors of tumor response of neuroendocrine tumor liver metastasis to transcatheter arterial bland embolization [J ] . Neuroendocrinology , 2020 , 110 ( 7/8 ): 697 - 704 . DOI: 10.1159/000504257 http://doi.org/10.1159/000504257 https://www.karger.com/Article/FullText/504257 https://www.karger.com/Article/FullText/504257

SIGAL D , TARTAR M , XAVIER M , et al . Activity of entrectinib in a patient with the first reported NTRK fusion in neuroendocrine cancer [J ] . J Natl Compr Canc Netw , 2017 , 15 ( 11 ): 1317 - 1322 . DOI: 10.6004/jnccn.2017.7029 http://doi.org/10.6004/jnccn.2017.7029 https://jnccn.org/doi/10.6004/jnccn.2017.7029 https://jnccn.org/doi/10.6004/jnccn.2017.7029

JONASCH E , DONSKOV F , ILIOPOULOS O , et al . Belzutifan for renal cell carcinoma in von hippel-lindau disease [J ] . N Engl J Med , 2021 , 385 ( 22 ): 2036 - 2046 . DOI: 10.1056/NEJMoa2103425 http://doi.org/10.1056/NEJMoa2103425 http://www.nejm.org/doi/10.1056/NEJMoa2103425 http://www.nejm.org/doi/10.1056/NEJMoa2103425

LEE E , RODON J , DEMEURE M , et al . Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC 1 or TSC 2 genes (PRECISION I) (1300) [J ] . Gynecol Oncol , 2023 , 176 : S185 .

浏览量

4529

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

晚期分化型甲状腺癌系统治疗的10年演进：2015与2025年版ATA指南对比分析

人工智能在类器官研究中的应用进展与挑战

胰腺神经内分泌肿瘤外科治疗理念的四种转变